An in-depth look at OLYMPIAD in HER2 negative breast cancer
Often times when we see promising data presented at a cancer conference, we interview a thought leader and post the expert opinion with additional commentary and insights.
ASCO17 OlympiAD Plenary
At ASCO, we decided to take a different approach, a twist on the usual fare… given that two of the phase 3 trials, OLYMPIAD and APHINITY, received significant attention and focus involved breast cancer, we reached out to numerous experts and curated their sentiments on both studies. For completeness and fair balance, these included industry and academic opinions.
Today, we begin with the OLYMPIAD trial presented by Dr Mark Robson on behalf of his colleagues exploring the role of the PARP inhibitor, olaparib (Lynparza), in HER2-negative metastatic breast cancer with germline BRCA mutations.
There’s a lot to consider here, not least is where do we go next from here and which PARP combination approaches are researchers most excited about?
To learn more about these sentiments and insights, subscribers can log-in or you can purchase access to BSB Premium Content below…
This content is restricted to subscribers
Chicago: Greetings from Peets Coffee in UIC Halstead where we finally take a moment to stop, catch a breath and reflect on the tsunami of data being presented at the McCormick centre over the last couple of days.
This week’s Fun Friday post highlights some important abstracts to watch out for in advance of ASCO 2017, so without much ado about nothing, you can check out our selections, some of which are likely to be controversial.
Although ASH and ASGCT are important meetings for CAR T cell therapies, there are still some intriguing data to be had at ASCO next month, including both oral and poster abstracts.
If there’s one topic that has generated a LOT of questions from BSB readers this month it is Puma Biotech’s neratinib in adjuvant breast cancer.
Before we get into our in-depth coverage based on the tumour type, target and modality landscapes, I wanted to take a moment to highlight five key abstracts that stood out for me as worthy of checking out in more detail once we get to Chicago.